125 related articles for article (PubMed ID: 7544517)
1. Characteristics of prostate cancer found with early detection regimens.
Brendler CB
Urology; 1995 Sep; 46(3 Suppl A):71-6. PubMed ID: 7544517
[TBL] [Abstract][Full Text] [Related]
2. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
3. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
Epstein JI; Chan DW; Sokoll LJ; Walsh PC; Cox JL; Rittenhouse H; Wolfert R; Carter HB
J Urol; 1998 Dec; 160(6 Pt 2):2407-11. PubMed ID: 9817393
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
Carter HB; Sauvageot J; Walsh PC; Epstein JI
J Urol; 1997 Jun; 157(6):2206-9. PubMed ID: 9146616
[TBL] [Abstract][Full Text] [Related]
5. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer.
Kawakami S; Kihara K; Fujii Y; Masuda H; Kobayashi T; Kageyama Y
Int J Urol; 2004 Aug; 11(8):613-8. PubMed ID: 15285751
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.
Cookson MS; Fleshner NE; Soloway SM; Fair WR
Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696
[TBL] [Abstract][Full Text] [Related]
8. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
9. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view.
Elgamal AA; Van Poppel HP; Van de Voorde WM; Van Dorpe JA; Oyen RH; Baert LV
J Urol; 1997 Jan; 157(1):244-50. PubMed ID: 8976263
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
[TBL] [Abstract][Full Text] [Related]
11. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
12. Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.
Stormont TJ; Farrow GM; Myers RP; Blute ML; Zincke H; Wilson TM; Oesterling JE
Urology; 1993 Jan; 41(1):3-8. PubMed ID: 7678359
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
Epstein JI; Walsh PC; Brendler CB
J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological study of nonpalpable and nonvisible (stage T1c) prostate cancer].
Egawa S; Kuwao S; Soh S; Ohori M; Kawakami T; Uchida T; Yokoyama E; Koshiba K
Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1108-16. PubMed ID: 7541874
[TBL] [Abstract][Full Text] [Related]
15. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
16. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
17. Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer.
Furuya Y; Fuse H; Nagakawa O; Masai M
Int J Clin Oncol; 2002 Apr; 7(2):109-13. PubMed ID: 12018107
[TBL] [Abstract][Full Text] [Related]
18. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Ohori M; Wheeler TM; Scardino PT
Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
[TBL] [Abstract][Full Text] [Related]
19. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
20. Are prostate carcinoma clinical stages T1c and T2 similar?
Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
